The University of Queensland’s BASE facility – within the AIBN – and Brisbane-based biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.
A new parcel of federal funding will help AIBN researchers produce clinical-grade mRNA products that are safer and better quality, and will potentially cost less.
Australian Institute for Bioengineering and Nanotechnology researchers have scored crucial funding wins as they push to create the next generation of medicines and treatments.
AIBN research facility BASE hosted an RNA Afternoon on April 7, with Australian experts discussing mRNA therapy advances – and impacts such as on liver disease treatment.
The success of the COVID-19 mRNA vaccines has demonstrated the potential of RNA therapies – and the University of Queensland is driving research and developing facilities to realise the potential.
A pilot facility at AIBN could be producing mRNA vaccines and cancer therapies for research and development within months after receiving backing from the Australian Government.
